"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
Jacob A. Moyer, BS
Advertisement
Articles by Jacob A. Moyer, BS
"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS.
Advertisement
Latest Updated Articles
Investigators highlight real-world data on nadofaragene firadenovec in NMIBCPublished: March 7th 2025 | Updated:
Nadofaragene firadenovec maintains safety, efficacy in real-world populationPublished: March 20th 2025 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
